Polysaccharide‐Based Drug Conjugates for Tumor Targeting

Saravanakumar, G.; Park, Jae Hyung; Kim, Kwangmeyung; Kwon, Ick Chan

doi:10.1002/9783527634057.ch23

Cited by 5 publications

(1 citation statement)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19,20 Natural and semisynthetic polysaccharides, namely, dextran, chitosan, hyaluronic acid, and pullulan, are excellent platforms to produce anticancer polymer therapeutics for combined drug delivery. 21 Indeed, these biodegradable and multivalent polymers can be derivatized with multiple copies of drugs and targeting agents. 7,18,22 Pullulan, in particular, is an attractive and versatile candidate for numerous biomedical applications, namely, drug delivery and tissue engineering.…”

Section: Introductionmentioning

confidence: 99%

Novel Pullulan Bioconjugate for Selective Breast Cancer Bone Metastases Treatment

et al. 2015

View full text Add to dashboard Cite

A novel polysaccharide bioconjugate was designed to selectively target breast cancer bone metastases using a bisphosphonate moiety (alendronate, ALN). Paclitaxel (PTX) was first covalently conjugated to pullulan (Pull) through a Cathepsin K-sensitive tetrapeptide spacer followed by a self-immolative aminobenzyl alcohol spacer to obtain Pull-(GGPNle-φ-PTX). ALN was then conjugated to the polymeric backbone of Pull-(GGPNle-φ-PTX) via a PEG spacer. The final bioconjugate Pull-(GGPNle-φ-PTX)-(PEG-ALN) was found to assemble into colloidal spherical structures, which were physically and chemically stable under physiological conditions. In vitro studies showed that Pull-(GGPNle-φ-PTX)-(PEG-ALN) had strong affinity for hydroxyapatite, which simulates the bone tissue. Paclitaxel was rapidly released from the bioconjugate by Cathepsin K cleavage under pathological conditions. All studies performed using human MDA-MB-231-BM (bone metastases-originated clone), murine 4T1 breast cancer cells, murine K7M2, and human SAOS-2 osteosarcoma cells showed that the bioconjugate exerted an enhanced antiproliferative activity compared to the conjugate without the ALN. Furthermore, the nanoconjugate inhibited the migration of cancer cells and further displayed potent anti-angiogenic activity. In conclusion, the results showed that this conjugate has an excellent potential for selective treatment of bone neoplasms such as breast cancer bone metastases and osteosarcoma.

show abstract